The device rapidly reduces the parasitaemia of severe Malaria patients who have been hospitalised and prescribed IV drug treatment.

While there are effective pharmaceutical treatments available, disease severity, recovery times and mortality are all strongly linked to a patient’s parasitaemia upon beginning drug treatment. Given the lengthy travel time required for many developing world patients to reach hospital many only get treatment once it’s too late. The key to tackling malaria lies in our ability to facilitate the rapid removal of infected red blood cells. When this is successfully carried out, a significant reduction of parasitaemia occurs – and that signifies the first steps on a patient's road to recovery.

Broad risk groups

Under 5s

Pregnant

Immune deficient patients

Significant worldwide burden

200k annual infant deaths

50% of the world at risk

Severe malaria high morbidity and mortality

Mortality rate 20%

Coma

Respiratory distress

Growing resistance to current treatment

Antibiotic resistance

Mosquito resistance to insecticides

Increasing cases

Pre-clinical results appear to be very encouraging, indicating that the MediSieve Filter could reduce a child's parasitaemia by over 90% in two hours. Magnetic haemofiltration offers the chance to turn back the clock for these patients by rapidly and safely reducing a patient’s parasitaemia. A one-off treatment of a severe patient could reduce mortality, accelerate symptom reduction, and prevent disease escalation.

Latest News

Neil Barker Joins MediSieve as a Quality Manager

Neil Barker Joins MediSieve as a Quality Manager
September 06, 2021

MediSieve Ltd, a biotech company which has developed an innovative blood filtration device, today announced the appointment of Neil Barker, as a Quality Manager. Neil brings to MediSieve a 40-year track record in quality and regulatory affairs, having held management positions at multiple engineeri...